---
title: "Here's How Much $100 Invested In Novo Nordisk 15 Years Ago Would Be Worth Today"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286340230.md"
description: "Novo Nordisk (NYSE:NVO) has delivered an annualized return of 29.58% over the past 15 years, outperforming the market by 17.52%. With a current market capitalization of $208.88 billion, a $100 investment in NVO stock 15 years ago would now be worth $4,873.71, highlighting the significant impact of compounded returns on investment growth."
datetime: "2026-05-13T23:15:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286340230.md)
  - [en](https://longbridge.com/en/news/286340230.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286340230.md)
---

# Here's How Much $100 Invested In Novo Nordisk 15 Years Ago Would Be Worth Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 15 years by 17.52% on an annualized basis producing an average annual return of 29.58%. Currently, Novo Nordisk has a market capitalization of $208.88 billion.

**Buying $100 In NVO:** If an investor had bought $100 of NVO stock 15 years ago, it would be worth **$4,873.71** today based on a price of $47.12 for NVO at the time of writing.

### Novo Nordisk's Performance Over Last 15 Years

![comp_fig](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1778714128_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada](https://longbridge.com/en/news/286343869.md)
- [FY2027 Earnings Estimate for NVO Issued By Erste Group Bank](https://longbridge.com/en/news/285887506.md)
- [Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial](https://longbridge.com/en/news/286239982.md)
- [BMO Capital Remains a Hold on Novo Nordisk (NVO)](https://longbridge.com/en/news/285956233.md)
- [3 deeply undervalued stocks you can buy for less than $100 right now](https://longbridge.com/en/news/286802600.md)